Orbicular Announces Health Canada Approval for a g-Ozempic (Semaglutide Injection) in Partnership with Apotex
May 04, 2026
New Delhi [India], May 4: Orbicular Pharmaceutical Technologies Pvt. Ltd., a specialty pharmaceutical company focused on complex generics and peptide-based therapeutics, today announced that a generic version of Ozempic (semaglutide injection), developed in partnership with Apotex, has received a Notice of Compliance (NOC) from Health Canada. The product will be marketed and commercialized in Canada by Apotex Inc., the applicant of record and Canada's largest pharmaceutical company.